Hartmut H Malluche

List of Publications by Year
in descending order

81	12,907	57752	58576
papers	citations	44 h-index	82 g-index

83	83	83	9803
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee. Journal of Bone and Mineral Research, 1987, 2, 595-610.	2.8	4,558
2	Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. Journal of Bone and Mineral Research, 2013, 28, 2-17.	2.8	2,023
3	Structural and cellular assessment of bone quality of proximal femur. Bone, 1993, 14, 231-242.	2.9	704
4	Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney International, 1994, 46, 855-861.	5.2	296
5	Renal osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and white patients. Journal of Bone and Mineral Research, 2011, 26, 1368-1376.	2.8	265
6	Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. American Journal of Kidney Diseases, 1995, 26, 622-631.	1.9	241
7	Prevention of Bone Loss in Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2003, 14, 2669-2676.	6.1	234
8	Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney International, 2001, 60, 1460-1468.	5.2	226
9	Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. American Journal of Kidney Diseases, 2016, 67, 559-566.	1.9	218
10	High Prevalence of Low Bone Turnover and Occurrence of Osteomalacia after Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2000, 11, 1093-1099.	6.1	211
11	Sclerostin and Dickkopf-1 in Renal Osteodystrophy. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 877-882.	4.5	210
12	Early chronic kidney diseaseâ€“mineral bone disorder stimulates vascular calcification. Kidney International, 2014, 85, 142-150.	5.2	178
13	1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trial. Kidney International, 1989, 35, 661-669.	5.2	156
14	Effects of Sevelamer Hydrochloride and Calcium Carbonate on Renal Osteodystrophy in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2008, 19, 405-412.	6.1	153
15	CKD-Induced Wingless/Integration1 Inhibitors and Phosphorus Cause the CKDâ€“Mineral and Bone Disorder. Journal of the American Society of Nephrology: JASN, 2014, 25, 1760-1773.	6.1	144
16	A new semiautomatic method for quantitative static and dynamic bone histology. Calcified Tissue International, 1982, 34, 439-448.	3.1	142
17	Quantitative bone histology in 84 normal American subjects. Calcified Tissue International, 1982, 34, 449-455.	3.1	129
18	Aluminium and bone disease in chronic renal failure. Nephrology Dialysis Transplantation, 2002, 17, 21-24.	0.7	118

#	Article	IF	Citations
19	Differences in Bone Quality in Low- and High-Turnover Renal Osteodystrophy. Journal of the American Society of Nephrology: JASN, 2012, 23, 525-532.	6.1	116
20	Bone Mineral Density and Serum Biochemical Predictors of Bone Loss in Patients with CKD on Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1254-1262.	4.5	111
21	Administration of PTH-(7-84) Antagonizes the Effects of PTH-(1-84) on Bone in Rats with Moderate Renal Failure. Endocrinology, 2003, 144, 1135-1138.	2.8	96
22	Low Bone Volumeâ€"A Risk Factor for Coronary Calcifications in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 450-455.	4.5	95
23	Osteoblastic Insufficiency Is Responsible for Maintenance of Osteopenia after Loss of Ovarian Function in Experimental Beagle Dogs*. Endocrinology, 1986, 119, 2649-2654.	2.8	91
24	Aluminum-Related Bone Disease in Mild and Advanced Renal Failure: Evidence for High Prevalence and Morbidity and Studies on Etiology and Diagnosis. American Journal of Nephrology, 1986, 6, 275-283.	3.1	87
25	Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties. Journal of Bone and Mineral Research, 1999, 14, 1768-1778.	2.8	87
26	Osteomalacia and Hyperparathyroid Bone Disease in Patients with Nephrotic Syndrome. Journal of Clinical Investigation, 1979, 63, 494-500.	8.2	85
27	Bone Markers Predict Cardiovascular Events in Chronic Kidney Disease. Journal of Bone and Mineral Research, 2008, 23, 1850-1858.	2.8	83
28	Bone disease after renal transplantation. Nature Reviews Nephrology, 2010, 6, 32-40.	9.6	82
29	The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?. Nephrology Dialysis Transplantation, 2004, 19, i9-i13.	0.7	74
30	High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis. Journal of the American Society of Nephrology: JASN, 2015, 26, 2534-2544.	6.1	74
31	Bone changes occurring early after cessation of ovarian function in beagle dogs: A histomorphometric study employing sequential biopsies. Journal of Bone and Mineral Research, 1990, 5, 263-272.	2.8	72
32	Evaluating bone quality in patients with chronic kidney disease. Nature Reviews Nephrology, 2013, 9, 671-680.	9.6	67
33	PREVENTION OF CANCELLOUS BONE LOSS BUT PERSISTENCE OF RENAL BONE DISEASE DESPITE NORMAL 1,25 VITAMIN D LEVELS TWO YEARS AFTER KIDNEY TRANSPLANTATION. Transplantation, 1995, 59, 1393-1400.	1.0	65
34	The link between bone and coronary calcifications in CKD-5 patients on haemodialysis. Nephrology Dialysis Transplantation, 2011, 26, 1010-1015.	0.7	65
35	Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis. Journal of the American Society of Nephrology: JASN, 2016, 27, 2475-2486.	6.1	65
36	Calcitonin Alters Bone Quality in Beagle Dogs. Journal of Bone and Mineral Research, 1997, 12, 1936-1943.	2.8	60

#	Article	IF	Citations
37	Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease. Kidney International, 2003, 64, 737-742.	5.2	58
38	1,25-Dihydroxyvitamin D Maintains Bone Cell Activity, and Parathyroid Hormone Modulates Bone Cell Number in Dogs[*]. Endocrinology, 1986, 119, 1298-1304.	2.8	57
39	Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy. Kidney International, 1996, 50, 515-520.	5.2	57
40	Update on vitamin D and its newer analogues: Actions and rationale for treatment in chronic renal failure. Kidney International, 2002, 62, 367-374.	5.2	56
41	Parathyroid Hormone/Parathyroid Hormone-Related Peptide Type 1 Receptor in Human Bone. Journal of Bone and Mineral Research, 2001, 16, 448-456.	2.8	55
42	A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. Journal of Bone and Mineral Research, 1993, 8, 1345-1355.	2.8	53
43	22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney International, 1999, 55, 821-832.	5.2	52
44	The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease. Kidney International, 2018, 93, 147-158.	5.2	51
45	Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease. Kidney International, 2017, 91, 86-95.	5.2	45
46	Management of hyperphosphataemia of chronic kidney disease: lessons from the past and future directions. Nephrology Dialysis Transplantation, 2002, 17, 1170-1175.	0.7	44
47	A program package for quantitative analysis of histologic structure and remodeling dynamics of bone. Computer Programs in Biomedicine, 1981, 13, 191-201.	0.7	43
48	Effects of Treatment of Renal Osteodystrophy on Bone Histology. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, S157-S163.	4.5	41
49	Relationship between Bone Histology and Markers of Bone and Mineral Metabolism in African-American Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1484-1493.	4.5	40
50	Intact PTH Combined With the PTH Ratio for Diagnosis of Bone Turnover in Dialysis Patients: A Diagnostic Test Study. American Journal of Kidney Diseases, 2010, 55, 897-906.	1.9	38
51	Low-Energy Fractures without Low T-Scores Characteristic of Osteoporosis. Journal of Bone and Joint Surgery - Series A, 2013, 95, e139.	3.0	38
52	SIRT6 deficiency culminates in low-turnover osteopenia. Bone, 2015, 81, 168-177.	2.9	31
53	Aluminum-Related Bone Disease. Blood Purification, 1988, 6, 1-15.	1.8	30
54	Bone Alkaline Phosphatase Isoforms in Hemodialysis Patients With Low Versus Non-Low Bone Turnover: AÂDiagnostic TestÂStudy. American Journal of Kidney Diseases, 2015, 66, 99-105.	1.9	29

#	Article	IF	Citations
55	FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis. Clinical Nephrology, 2014, 82 (2014), 287-295.	0.7	28
56	Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure. BioMed Research International, 2015, 2015, 1-9.	1.9	27
57	Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors. Osteoporosis International, 2018, 29, 125-134.	3.1	27
58	Calcitonin prevents bone loss but decreases osteoblastic activity in ovariohysterectomized beagle dogs. Journal of Bone and Mineral Research, 1996, 11, 446-455.	2.8	25
59	Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers. Clinical Nephrology, 2019, 91, 222-230.	0.7	24
60	Isolation and complete amino acid sequence of osteocalcin from canine bone. Journal of Bone and Mineral Research, 1993, 8, 733-743.	2.8	21
61	Sotatercept Safety and Effects onÂHemoglobin, Bone, and Vascular Calcification. Kidney International Reports, 2019, 4, 1585-1597.	0.8	21
62	A Survey Study of Self-Rated Patientsâ€™ Knowledge About AKI in a Post-Discharge AKI Clinic. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811983070.	1.1	19
63	Bone biopsy in patients with osteoporosis. Current Osteoporosis Reports, 2007, 5, 146-152.	3.6	18
64	Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease. Kidney International, 2016, 90, 828-834.	5.2	18
65	Use and indication of vitamin D and vitamin D analogues in patients with renal bone disease. Nephrology Dialysis Transplantation, 2002, 17, 6-9.	0.7	16
66	Effects of 6 Months Therapy with 1,25 (OH)2D3 on Bone Disease of Dialysis Patients. Contributions To Nephrology, 1980, 18, 98-104.	1.1	15
67	Aluminum: Toxin or Innocent Bystander in Renal Osteodystrophy. American Journal of Kidney Diseases, 1985, 6, 336-341.	1.9	15
68	Long-Term Effects of 1,25(OH)2 D3 on Clinical and Biochemical Derangements of Divalent Ions in Dialysis Patients. Contributions To Nephrology, 1980, 18, 42-54.	1.1	14
69	Calcitriol pulse therapy in patients with end-stage renal failure. Current Opinion in Nephrology and Hypertension, 1994, 3, 615-619.	2.0	14
70	Longâ€term outcomes and management considerations after parathyroidectomy in the dialysis patient. Seminars in Dialysis, 2019, 32, 541-552.	1.3	13
71	Biomarkers of Bone Turnover Identify Subsets of Chronic Kidney Disease Patients at Higher Risk for Fracture. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2903-e2911.	3.6	13
72	Diagnosis of low bone mass in CKD-5D patients. Clinical Nephrology, 2016, 85 (2016), 77-83.	0.7	13

#	Article	IF	Citations
73	Coronary artery calcification in CKD-5D â€¨patients is tied to adverse cardiac function â€¨and increased mortality. Clinical Nephrology, 2016, 86, 291-302.	0.7	12
74	Higher mineralized bone volume is associated with a lower plain X-Ray vascular calcification score in hemodialysis patients. PLoS ONE, 2017, 12, e0179868.	2.5	11
75	Importance of bone turnover for therapeutic decisions in patients with CKD-MBD. Kidney International, 2021, 100, 502-505.	5.2	10
76	Regulation of 25-hydroxyvitamin D3 metabolism in cultures of osteoblastic cells. Journal of Bone and Mineral Research, 1990, 5, 815-823.	2.8	8
77	Low Turnover Renal Osteodystrophy With Abnormal Bone Quality and Vascular Calcification in Patients With Mild-to-Moderate CKD. Kidney International Reports, 2022, 7, 1016-1026.	0.8	8
78	The Role of Alterations in Alpha-Klotho and FGF-23 in Kidney Transplantation and Kidney Donation. Frontiers in Medicine, 2022, 9, .	2.6	6
79	Bone Quality and Fractures in Women With Osteoporosis Treated With Bisphosphonates for 1 to 14â€‰Years. JBMR Plus, 2021, 5, e10549.	2.7	5
80	Renal Osteodystrophy Is a Multifaceted Disease with No Uniform Therapy. Seminars in Dialysis, 1993, 6, 210-214.	1.3	3
81	Response to â€œLow turnover bone disease in early CKD stagesâ€• Kidney International Reports, 2022, , .	0.8	0